Quotient Sciences

***Live: Tuesday, November 17, 2020 at 11am EDT| 8am PDT| 4pm GMT| 5pm CET***Oncology drugs dominate today’s industry pipeline, increasing the pressure on pharmaceutical scientists to get medications to patients as quickly as possible. But does the focus on speed mean sacrifices are made elsewhere in the development plan? Drug developers need to be mindful of the development challenges that come with oncology drug products in order to accelerate to proof-of-concept and onwards towards a successful commercial launch. *** On demand available after final airing until Nov. 17, 2021.***

***Live: Wednesday, October 28, 2020 at 11am EDT| 8am PDT| 3pm GMT| 4pm CET*** With over 300 million people worldwide living with one or more identified rare diseases, the development of new treatments to address these unmet clinical needs is an area of significant focus in the pharmaceutical industry. But does the focus on speed mean sacrifices have to be made elsewhere in the development plan for orphan drugs? ***On demand available after final airing until Oct. 28, 2021***

This whitepaper will cover five areas for consideration by oncology drug developers & the potential solutions in development, manufacturing & supply that are emerging.

This white paper addresses the principal CMC challenges for the developers of orphan drugs and highlights the potential solutions which are emerging.